The use of a botulinum toxin, in particular toxin type A, in the preparation of a pharmaceutical composition for treating urinary incontinence. The botulinum toxin may be formulated in a pharmaceutically acceptable formulation for example as a liquid, a powder, a cream, an emulsion, a pill, a troche, a suppository, a suspension, or a solution, and administered into the urinary tract of a human male or a human female.